Oxygen-evolving hollow polydopamine alleviates tumour hypoxia for enhancing photodynamic therapy in cancer treatment. Issue 23 (3rd November 2022)

• Record Type: Journal Article
• Authors: Zhan, Qichen; Han, Xuan; Mu, Jiankang; Shi, Xianqing; Zheng, Yuhan; Wang, Ting; Cao, Tao; Xi, Yulu; Weng, Zhongpei; Wang, Xiaoqing; Cao, Peng
• Is Part Of: Nanoscale advances. Volume 4:Issue 23(2022)
• Page Start: 5021
• Page End: 5026
• Publication Date: 2022-11-03
• Subjects: 620.5
• DOI: 10.1039/d2na00549b
• Languages: English
• ISSNs: 2516-0230

Abstract

Abstract : O2 -evolving hollow polydopamine (HPDA) based on an O2 bubble template is designed as a carrier for zinc phthalocyanine (ZnPc) to fabricate nanomedicine (HZNPs). HZNPs could alleviate tumor hypoxia and enhance PDT-anticancer efficiency. Abstract : Hypoxia, a characteristic hallmark of solid tumours, restricts the therapeutic effect of photodynamic therapy (PDT) for cancer treatment. To address this issue, a facile and nanosized oxygen (O2 ) bubble template is established by mixing oxygenated water and water-soluble solvents for guiding hollow polydopamine (HPDA) synthesis, and O2 is encapsulated in the cavity of HPDA. HPDA with abundant catechol is designed as a carrier for zinc phthalocyanine (ZnPc, a boronic acid modified photosensitizer) via borate ester bonds to fabricate nanomedicine (denoted as HZNPs). The in vitro and in vivo results indicate that O2 -evolving HZNPs could alleviate tumour hypoxia and enhance PDT-anticancer efficiency. Melanin-like HPDA with a photothermal conversion rate ( η ) of 38.2% shows excellent synergistic photothermal therapy (PTT) efficiency in cancer treatment.